Trial Profile
A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 19 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.
- 13 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 14 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.